)
Overview
<ul>
<li>US biotechnology firm’s 2025 net loss narrowed, beating analyst expectations</li>
<li>Collaboration revenue for 2025 surged, driven by Bristol-Myers Squibb agreement</li>
<li>Company completed $135 mln private placement, extending cash runway into Q1 2029</li>
</ul>
Outlook
<ul>
<li>Century expects to submit CNTY-813 IND in 4Q 2026, with initial clinical data in 2H 2027</li>
<li>Company expects CNTY-308 to enter the clinic in 2026, pending regulatory clearance</li>
<li>Century anticipates updated preliminary clinical data from the CARAMEL study in 2026</li>
</ul>
Result Drivers
<ul>
<li>COLLABORATION REVENUE - Surge in collaboration revenue attributed to Bristol-Myers Squibb agreement</li>
<li>LOWER R&amp;D AND G&amp;A COSTS - Decline in research and development and administrative expenses due to reduced personnel, manufacturing, and legal costs Company press release:</li>
</ul>
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
<h3>FY $109.16</h3>
Collabor mln
ation
Revenue
FY Net Beat -$9.58 -$14.72
Income mln mln (3
Analysts
)
FY Beat -$17.27 -$20.86
Operatin mln mln (3
g Income Analysts
)
FY Basic -$0.14
<h3>EPS</h3>
<h3>FY $126.43</h3>
Operatin mln
g
Expenses
Analyst Coverage
<ul>
<li>The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 5 “strong buy” or “buy”, 1 “hold” and no “sell” or “strong sell”</li>
<li>The average consensus recommendation for the biotechnology &amp; medical research peer group is “buy”</li>
<li>Wall Street’s median 12-month price target for Century Therapeutics Inc is $4.00, about 46.5% above its March 11 closing price of $2.73 For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</li>
</ul>

IBBQ

Reuters

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

ProShares Ultra Health Care ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

iShares US Pharma

iShares Biotechnology ETF

Century Therapeutics

Health Care Select Sector SPDR

Direxion Pharma & Medical Bull 3X

Ark Genomic Revolution ETF

VG Health

VanEck Biotech ETF

iShares Global Healthcare

Bristol Myers Squibb

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

Century Therapeutics 2025 net loss narrows beating estimates